Traws Pharma, Inc.
TRAWHealthcare|Biotechnology|US
$0.22
+0.00 (+0.82%)
Cash / Share
$0.29
Clinical Trials (38)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07371650 This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza | Influenza | P2 | Active | 105 | RCT, Open-label | TRX-100, Standard of Care (SOC) |
| NCT07526506 Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers | Healthy Volunteer | P1 | Recruiting | 32 | RCT, Double-blind | TRX-100, Placebo |
| NCT01241500 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts | Myelodysplastic Syndromes, MDS | P3 | Completed | 299 | RCT, Open-label | ON 01910.Na |
| NCT01360853 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | P3 | Completed | 160 | RCT, Open-label | ON 01910.Na, Gemcitabine, Gemcitabine |
| NCT02562443 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | Myelodysplastic Syndrome, MDS | P3 | Terminated | 372 | RCT, Open-label | rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC), best supportive care (BSC) |
| NCT01928537 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts | P3 | Completed | 67 | Open-label | rigosertib sodium |
| NCT00906334 Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | Myelodysplastic Syndrome | P2 | Completed | 14 | Open-label | ON 01910.Na, ON 01910.Na |
| NCT00856791 Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | Ovarian Cancer | P2 | Completed | 1 | Open-label | ON 01910.Na |
| NCT01904682 Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs | Myelodysplastic Syndromes | P2 | Completed | 45 | Open-label | Oral rigosertib |
| NCT01807546 Oral Rigosertib for Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | P2 | Completed | 64 | Open-label | rigosertib |
| NCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | Influenza | P2 | Not Yet Recruiting | 165 | RCT, Double-blind | TRX-100, Placebo, Influenza A/France/759/2021 (H1N1) virus |
| NCT04263090 Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | Non-small Cell Lung Cancer, Adenocarcinoma | P1P2 | Completed | 25 | Open-label | Rigosertib, Nivolumab |
| NCT01167166 Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | P1P2 | Completed | 30 | Open-label | rigosertib |
| NCT02730884 Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia | Leukemia, Myelofibrosis | P2 | Terminated | 3 | Open-label | Rigosertib |
| NCT00867061 Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) | Myelodysplastic Syndrome | P1P2 | Withdrawn | — | Open-label | ON 01910.Na Concentrate |
| NCT01926587 Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | Myelodysplastic Syndrome, Acute Myeloid Leukemia | P1P2 | Completed | 45 | Open-label | oral rigosertib, Azacitidine |
| NCT00854945 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | Myelodysplastic Syndrome, Acute Myeloid Leukemia | P1P2 | Completed | 36 | Open-label | ON 01910.Na |
| NCT01584531 Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | Myelodysplastic Syndrome, MDS | P2 | Completed | 82 | Open-label | rigosertib |
| NCT05705505 Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies | Endometrioid Endometrial Cancer | P1P2 | Unknown | 60 | Open-label | Narazaciclib, Letrozole 2.5mg |
| NCT07157007 Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 | COVID - 19 | P2 | Completed | 93 | RCT, Open-label | Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060) |
| NCT02168725 Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | Neoplasms, Advanced Solid Tumor | P1 | Terminated | 26 | Open-label | briciclib |
| NCT02030639 Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers | Healthy | P1 | Completed | 6 | Open-label | rigosertib |
| NCT01049113 Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | Lymphoma, Acute Lymphocytic Leukemia | P1 | Terminated | 7 | Open-label | ON 013105 |
| NCT02075034 Three Dosing Schedules of Oral Rigosertib in MDS Patients | Myelodysplastic Syndrome | P1 | Withdrawn | — | RCT, Open-label | rigosertib |
| NCT04739293 Study of ON 123300 in Patients With Advanced Cancer | Solid Tumors, Adult | P1 | Unknown | 36 | Open-label | ON123300 |
| NCT00854646 Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | P1 | Completed | 22 | Open-label | ON 01910.Na |
| NCT02107235 Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | Head and Neck Neoplasms, Carcinoma, Squamous Cell | P1 | Completed | 2 | Open-label | oral rigosertib, cisplatin |
| NCT01538563 Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | Solid Tumors, Advanced Cancer | P1 | Completed | 42 | Open-label | rigosertib sodium |
| NCT01538537 Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer | Advanced Cancer, Solid Tumors | P1 | Completed | 29 | Open-label | rigosertib sodium |
| NCT06402136 Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers | Healthy Volunteers Only | P1 | Completed | 57 | RCT, Double-blind | 83-0060, Placebo |
| NCT01125891 Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors | Malignant Neoplasmas, Solid Tumors | P1 | Completed | 39 | Open-label | gemcitabine, ON 01910.Na |
| NCT00861328 Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin | Advanced Solid Tumors | P1 | Completed | 18 | Open-label | ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin |
| NCT01168011 Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors | Solid Tumor | P1 | Completed | 68 | Open-label | rigosertib |
| NCT06757738 A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers | Healthy Volunteer Study | P1 | Completed | 66 | RCT, Double-blind | TRX-100, Placebo |
| NCT00861783 Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | Hepatoma, Advanced Solid Tumor | P1 | Completed | 16 | Open-label | irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na |
| NCT01165905 Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors | Solid Tumor | P1 | Completed | 10 | Open-label | ON 01910.Na, Gemcitabine |
| NCT01048619 Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome | Myelodysplastic Syndrome | P1 | Completed | 36 | Open-label | ON 01910.Na |
| NCT04177498 Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC | Recessive Dystrophic Epidermolysis Bullosa | Early P1 | Completed | 3 | Open-label | Rigosertib Sodium |